Radiat Oncol J.
2013 Dec;31(4):199-205. 10.3857/roj.2013.31.4.199.
Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report
- Affiliations
-
- 1Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ysk@amc.seoul.kr
- 2Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- KMID: 2051139
- DOI: http://doi.org/10.3857/roj.2013.31.4.199
Abstract
- PURPOSE
To assess the clinical efficacy and toxicity of whole pelvic intensity-modulated radiotherapy (WP-IMRT) for high-risk prostate cancer.
MATERIALS AND METHODS
Patients with high-risk prostate cancer treated between 2008 and 2013 were reviewed. The study included patients who had undergone WP-IMRT with image guidance using electronic portal imaging devices and/or cone-beam computed tomography. The endorectal balloon was used in 93% of patients. Patients received either 46 Gy to the whole pelvis plus a boost of up to 76 Gy to the prostate in 2 Gy daily fractions, or 44 Gy to the whole pelvis plus a boost of up to 72.6 Gy to the prostate in 2.2 Gy fractions.
RESULTS
The study cohort included 70 patients, of whom 55 (78%) had a Gleason score of 8 to 10 and 50 (71%) had a prostate-specific antigen level > 20 ng/mL. The androgen deprivation therapy was combined in 62 patients. The biochemical failure-free survival rate was 86.7% at 2 years. Acute any grade gastrointestinal (GI) and genitourinary (GU) toxicity rates were 47% and 73%, respectively. The actuarial rate of late grade 2 or worse toxicity at 2 years was 12.9% for GI, and 5.7% for GU with no late grade 4 toxicity.
CONCLUSION
WP-IMRT was well tolerated with no severe acute or late toxicities, resulting in at least similar biochemical control to that of the historic control group with a small field. The long-term efficacy and toxicity will be assessed in the future, and a prospective randomized trial is needed to verify these findings.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparison study of intensity modulated arc therapy using single or multiple arcs to intensity modulated radiation therapy for high-risk prostate cancer
- Evolution of Radiotherapy: High-precision Radiotherapy
- Is the Use of Intensity-Modulated Radiotherapy Beneficial for Pancreatic Cancer Patients?
- Hypofractionated intensity-modulated radiotherapy in patients with localized prostate cancer: a preliminary study
- Radiobiological analysis of preliminary results of a phase II study of pelvic hypofractionated and accelerated radiotherapy for high-risk prostate cancer patients
